FDMT - 4D Molecular Therapeutics, Inc.
NEXT EARNINGS:
Feb 27, 2026
(in 3 days)
EPS Est: $-0.53
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$25.33
DETAILS
HIGH:
$33.00
LOW:
$17.00
MEDIAN:
$26.00
CONSENSUS:
$25.33
UPSIDE:
151.54%
Market Cap:
513.65M
Volume:
645,328
Avg Volume:
897,588
52 Week Range:
2.235-12.34
Sector:
Healthcare
Industry:
Biotechnology
Beta:
3.01
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
227
IPO Date:
2020-12-11
EPS (TTM):
-2.98
P/E Ratio:
-1.87
Revenue (TTM):
37,000
Total Assets:
560.38M
Total Debt:
24.61M
Cash & Equiv:
149.34M
Rev Growth (5Y):
-64.9%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-35.4%
Debt/Equity:
0.05
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2025-11-10 | $-1.01 | $-1.02 | +1.0% | $90000 | $30.9M | -99.7% |
| 2025-08-11 | $-0.98 | $-0.88 | -11.4% | $15000 | $4670 | +221.2% |
| 2025-05-08 | $-0.86 | $-0.84 | -2.4% | $14000 | $537500 | -97.4% |
| 2025-02-28 | $-0.90 | $-0.80 | -12.5% | $1000 | $2.3M | -100.0% |
| 2024-11-13 | $-0.79 | $-0.67 | -17.9% | $3000 | $2.2M | -99.9% |
| 2024-08-08 | $-0.63 | $-0.72 | +12.5% | $5000 | $1.3M | -99.6% |
| 2024-05-09 | $-0.66 | $-0.73 | +9.6% | $28000 | $780000 | -96.4% |
| 2024-02-29 | $-0.77 | $-0.68 | -13.2% | $19000 | $2.4M | -99.2% |
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 37,000 | 20.72M | 3.13M | 18.04M | 13.61M | 6.99M | 14.13M | 5.79M |
| Net Income | (160.87M) | (100.84M) | (107.49M) | (71.32M) | (56.69M) | (49.31M) | (9.55M) | (11.22M) |
| EPS | -2.98 | -2.58 | -3.12 | -2.46 | -2.12 | -2.00 | -0.76 | -0.76 |
| Total Assets | 560.38M | 339.89M | 261.85M | 353.49M | 288.33M | 58.23M | 96.97M | 27.32M |
| Total Debt | 24.61M | 14.67M | 16.12M | 16.45M | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 149.34M | 249.11M | 52.35M | 153.00M | 276.73M | 49.65M | 91.76M | 23.85M |
| Operating Cash Flow | (134.59M) | (75.79M) | (86.69M) | (69.13M) | (50.91M) | (36.71M) | (16.25M) | 8.24M |
| Free Cash Flow | (138.37M) | (78.56M) | (98.22M) | (78.24M) | (51.91M) | (39.91M) | (16.67M) | 7.66M |
| FCF per Share | -2.57 | -2.01 | -3.04 | -2.82 | -1.95 | -1.51 | -1.33 | 0.52 |
| Book Value | 510.61M | 307.83M | 231.34M | 319.11M | 256.39M | (72.97M) | (27.59M) | (19.59M) |
| Cash & ST Investments | 424.88M | 288.23M | 213.55M | 247.78M | 276.73M | 49.65M | 91.76M | 23.85M |
| ROC Equity | -0.32 | -0.33 | -0.46 | -0.22 | -0.22 | N/A | N/A | N/A |